NICE approval for arthritis antibody

Patients with rheumatoid arthritis can now be treated with tocilizumab (RoActemra) on the NHS.

Tocilizumab is a humanized monoclonal antibody that prevents interleukin-6 binding to its receptor.
Tocilizumab is a humanized monoclonal antibody that prevents interleukin-6 binding to its receptor.

NICE has recommended tocilizumab, in combination with methotrexate, for the treatment of moderate to severe rheumatoid arthritis that has not responded to other TNF inhibitors. Patients must have also either failed to respond to, or be unsuitable, for treatment with rituximab.

Patients already receiving tocilizumab who do not meet the above criteria should be able to continue treatment until they and their doctor decide it is appropriate to stop, says NICE.

NICE has previously approved the TNF inhibitors adalimumab, etanercept, infliximab and certolizumab pegol for the treatment of rheumatoid arthritis.

NICE guidance on tocilizumab

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...